ライフサイエンスコーパス: vascular event

1 n for angina, heart failure, or a peripheral vascular event).

2 ammatory event (major surgery, infection, or vascular event).

3 42 patients (19.6%) had at least 1 recurrent vascular event.

4 table angina, heart failure, or a peripheral vascular event.

5 itional 15% reduction in the risk of a major vascular event.

6 nts with less than 1% annual risk of a major vascular event.

7 ailure model which is not based on a primary vascular event.

8 infection and prevent the development of new vascular events.

9 m underwent therapeutic procedures for these vascular events.

10 ponse rate, RBC transfusions, and thrombotic vascular events.

11 ng disease and/or unrelated arteriosclerotic vascular events.

12 ication of patients at higher risk for acute vascular events.

13 consider absence of disease progression and vascular events.

14 y aspirin versus no aspirin in prevention of vascular events.

15 -15% reduction of annual incidence rates for vascular events.

16 e and the first occurrence of a composite of vascular events.

17 esion and thrombus formation during ischemic vascular events.

18 edictive values for incident major occlusive vascular events.

19 ials in secondary prevention from thrombotic vascular events.

20 independent risk factor for stroke and other vascular events.

21 re in the arterial system and to the risk of vascular events.

22 nal risk stratification in predicting future vascular events.

23 , which affect the risk of both bleeding and vascular events.

24 is study, we examined an MeDi in relation to vascular events.

25 n MeDi was associated with decreased risk of vascular events.

26 AD-related neurodegeneration, is preceded by vascular events.

27 isk of cerebral, but not coronary, ischaemic vascular events.

28 influenza by vaccination reduces the risk of vascular events.

29 us control done originally for prevention of vascular events.

30 ed with a transient increase in the risk for vascular events.

31 did not result in a significant reduction in vascular events.

32 higher incidence of major strokes and major vascular events.

33 pertension is associated with a high risk of vascular events.

34 influences in governing the timing of these vascular events.

35 hether such a reduction will result in fewer vascular events.

36 been recently used in the settings of acute vascular events.

37 the risk, manifestation, and progression of vascular events.

38 average, and higher relative risk for future vascular events.

39 eighed by a long-term reduction in recurrent vascular events.

40 ithout diabetes mellitus in preventing major vascular events.

41 opment for the treatment of atherothrombotic vascular events.

42 effective than aspirin in preventing serious vascular events.

43 These patients are at high risk of future vascular events.

44 tiplatelet agent for preventing and treating vascular events.

45 ma progression was associated with recurrent vascular events.

46 emic optic neuropathy as well as for retinal vascular events.

47 risk factors to determine and reduce risk of vascular events.

48 pecific physiology, may increase the risk of vascular events.

49 f statin therapy for the prevention of major vascular events.

50 lthough it did not have an adverse effect on vascular events.

51 and aspirin prevents reinfarction and other vascular events.

52 domized controlled trial that reported major vascular events.

53 itors significantly reduce the risk of major vascular events.

54 approach for prevention of atherothrombotic vascular events.

55 arotid plaque are associated with subsequent vascular events.

56 zumab does not increase the risk of systemic vascular events.

57 ations between incidental carotid plaque and vascular events.

58 ation in estimated 10-year risk of recurrent vascular events.

59 d with progressive atherosclerosis and acute vascular events.

60 IMT have all relevant with the occurrence of vascular events.

61 lded a 12% proportional reduction in serious vascular events (0.51% aspirin vs 0.57% control per year

62 70-0.92; p < 0.01) and a lower risk of major vascular events (0.91; 0.86-0.96; p < 0.001).

63 nterval [CI]: 0.68 to 0.85) for any ischemic vascular event, 0.74 (95% CI: 0.65 to 0.85) for ischemic

64 no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients

65 P=0.03), as was the rate of the first major vascular event (11.0 vs. 12.8; hazard ratio, 0.86; 95% C

66 significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an

67 d vascular death (2.38 [1.50-3.78]), and all vascular events (2.48 [1.57-3.91]), after adjusting for

68 lded a greater absolute reduction in serious vascular events (6.7%vs 8.2% per year, p<0.0001), with a

69 Of 3096 acute cerebral or peripheral vascular events, 748 (24.2%) were AF-related.

70 Aspirin reduced major vascular events (8.7%/yr versus 5.7%/yr; HR, 0.66; 95% C

71 The relative risk (RR) of major vascular events (a composite of cardiovascular death, ac

72 meta-analysed the risk ratio (RR) for major vascular events (a composite of cardiovascular death, my

73 ffects of allocation to anacetrapib on major vascular events (a composite of coronary death, myocardi

74 Over a mean follow-up of 9 y, 518 vascular events accrued (171 ischemic strokes, 133 MIs,

75 f SBP maintained at such levels with risk of vascular events after a recent ischemic stroke is unclea

76 opidogrel plus aspirin, to prevent secondary vascular events after stroke or TIA.

77 ored Hospital-based Risk reduction to Impede Vascular Events after Stroke) intervention improved bloo

78 Long-term data on recurrent vascular events after young stroke are limited.

79 s to examine the long-term risk of recurrent vascular events after young stroke.

80 oses are more effective for preventing major vascular events, albeit with evidence of increased toxic

81 tity of sleep may be independently linked to vascular events although prospective and multiethnic stu

82 carotid plaque, plaque characteristics, and vascular events among PLWHIV is unclear.

83 rials of nonstatin therapy with 25 218 major vascular events and 177 088 participants from 25 trials

84 n I and BNP were associated with the risk of vascular events and all-cause mortality.

85 Associations between vascular events and baseline concentrations of cholester

86 tinin is associated with increased renal and vascular events and death compared to its alternatives.

87 edication adherence and rates of first major vascular events and decreased patient spending without i

88 count for all blood-pressure-related risk of vascular events and for the benefits of antihypertensive

89 ressure variability in prediction of risk of vascular events and in accounting for benefits of antihy

90 d not significantly reduce the risk of major vascular events and increased the risk of serious advers

91 life threatening or treatable causes such as vascular events and malignant diseases, and patients sho

92 hat calcification is causal in precipitating vascular events and mediating chronic cardiovascular dam

93 thereafter followed up for the occurrence of vascular events and mortality within the Three-City Stud

94 e Trial, UK-TIA Aspirin Trial) prevention of vascular events and one trial of different doses of aspi

95 ated LOOH levels were predictive of nonfatal vascular events and procedures in patients with stable C

96 23 (95% CI 1.44 to 3.44; p = 0.0003) for all vascular events and procedures.

97 All patients are alive and well with no new vascular events and resolution of hematological and immu

98 le of C-reactive protein (CRP) in predicting vascular events and response to statin therapy remains u

99 EDS is independently associated with future vascular events and stroke in particular in healthy comm

100 isorders remains largely based on preventing vascular events and symptomatic control, with allogeneic

101 n an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL choles

102 Treatment of HDL to Reduce the Incidence of Vascular Events and The Atherothrombosis Intervention in

103 the occurrence of all (first and subsequent) vascular events and the effect of atorvastatin to reduce

104 The predictive value of N-BNP for occlusive vascular events and the effects of statins in people wit

105 age risk, 660,000 person-years, 3554 serious vascular events) and 16 secondary prevention trials (17,

106 events or revascularization, the first major vascular event, and health expenditures.

107 ssociated with higher risk for stroke, major vascular events, and composite after full adjustment amo

108 course of effects on incident cancer, major vascular events, and major extracranial bleeds, with str

109 e probabilities of hepatocellular carcinoma, vascular events, and nonhepatic cancers were not differe

110 th lower rates of all-cause mortality, major vascular events, and revascularizations compared with pl

111 d kidney function decline with stroke, major vascular events, and the composite of stroke, death, maj

112 Clinical features, presenting symptoms, and vascular events are reviewed for the first 447 patients

113 The mechanisms by which hypertension causes vascular events are unclear.

114 e mechanisms driving rhythmicity of ischemic vascular events are unknown.

115 ischemic attack, vascular deaths, and major vascular events as defined by the Antiplatelet Trialists

116 ies of PCSK9 Inhibition and the Reduction of Vascular Events), assessing evolocumab and bococizumab,

117 me measure was the risk ratio (RR) for major vascular events associated with absolute reductions in l

118 ible for myeloproliferation (and potentially vascular events) associated with myeloproliferative diso

119 rization is associated with fewer peripheral vascular events at 6 months.

120 ween influenza vaccination and major adverse vascular events because the association remains uncertai

121 there was no difference in the incidence of vascular events between immunosuppressed and immunocompe

122 t baseline, and 185 had come up to the final vascular events (brain infarction, intracerebral hemorrh

123 d not significantly reduce the risk of major vascular events but did increase the risk of serious adv

124 sease, aspirin significantly reduced serious vascular events but increased major bleeding.

125 steinemia confers a high risk for thrombotic vascular events, but homocysteine-lowering therapies hav

126 tion of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding.

127 01) partly accounted for the reduced risk of vascular events, but reduced visit-to-visit variability

128 Lowering of LDL cholesterol reduces major vascular events, but whether more intensive therapy safe

129 by 17 mg/dl (0.44 mmol/l), and reduced major vascular events by 9% over 4 years, but anaceptrapib was

130 tion reducing the annual rate of these major vascular events by just over a fifth.

131 sion, but rather the prevention of recurrent vascular events by more powerful platelet inhibition or

132 ents, the modest benefit in reducing serious vascular events can be offset by the increased risk of b

133 s included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarc

134 twice the excess risk of fatal and nonfatal vascular events, compared with men with type 1 diabetes.

135 A vascular event comprising the secondary end point occurr

136 11-18; p<0.0001) further reduction in major vascular events, consisting of separately significant re

137 The timing of retinal vascular events correlated more closely with postconcept

138 riate analysis, the risk of mortality and of vascular events decreased across the categories of ideal

139 wo secondary end points were (1) all initial vascular events defined as a composite of a primary end

140 The primary endpoint was major vascular events, defined as coronary death, myocardial i

141 disease are at increased risk for subsequent vascular events despite effective use of statins to lowe

142 an ancestry, 2,504 (13.0%) had a first major vascular event during 4 years median follow-up: 1,216 (1

143 d trial of simvastatin versus placebo (>5000 vascular events during 5.3 years of follow-up among 20 0

144 ssociated with reduced risk of major adverse vascular events during influenza seasons when the influe

145 rong relationship with the new occurrence of vascular events, especially the brain infarction (HR: 2.

146 ing is associated with a lower risk of major vascular events, even after adjustment for LDL-C lowerin

147 less than 1.8 mmol/L had a 55% reduction in vascular events (event rate 1.11 vs 0.51 per 100 person-

148 roke remain at substantial risk of recurrent vascular events for decades, suggesting that the underly

149 essed whether rimonabant would improve major vascular event-free survival.

150 0 000 patients would typically prevent major vascular events from occurring in about 1000 patients (i

151 dverse impact of these side-effects on major vascular events has already been taken into account in t

152 An association between infections and vascular events has been observed, but the specific effe

153 Prevention of vascular events has been so far the main objective of th

154 e coronavirus disease 2019 (COVID-19), major vascular events have been reported.

155 te coronary, cerebrovascular, and peripheral vascular events have common underlying arterial patholog

156 dverse effects of calcium supplementation on vascular events have raised widespread concern.

157 ma progression was associated with composite vascular events (hazard ratio 5.8, 95% confidence interv

158 as associated with a 5% reduced risk for all vascular events (hazard ratio [HR]: 0.95; 95% confidence

159 -Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), but its net effects on he

160 46), HDL-C was not associated with recurrent vascular events (HR: 1.02; 95% CI: 0.98 to 1.07) irrespe

161 hat statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infar

162 ional phenotypes that subsequently influence vascular events important for adaptive remodeling.

163 the IMT and IMT-Progression as Predictors of Vascular Events (IMPROVE) cohort, to identify the functi

164 623 (73%) coronary, and 147 (78%) peripheral vascular events in 12 886 (14%) individuals aged 65 year

165 s [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) stud

166 a prospective incidence cohort study of all vascular events in a population of 92 728 people residin

167 tudy is a prospective incidence study of all vascular events in a population of 92 728 people residin

168 ution of estimated 10-year risk of recurrent vascular events in a secondary prevention population.

169 tatin regimens reduces the risk of occlusive vascular events in a wide range of individuals.

170 Statin therapy safely reduces the risk of vascular events in a wide range of patients.

171 eepiness and the risk of ischemic stroke and vascular events in an elderly, multiethnic prospective c

172 UPITER trial found that rosuvastatin reduces vascular events in apparently healthy subjects with elev

173 -type natriuretic peptide (N-BNP) to predict vascular events in high-risk people and to test whether

174 The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study o

175 a subset of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants.

176 REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immu

177 in the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) trial cohort.

178 alues <0.15), we recorded a 65% reduction in vascular events in participants allocated to rosuvastati

179 s were used to evaluate the risk of HDL-C on vascular events in patients using no, usual dose, or int

180 w-dose rivaroxaban and aspirin reduced major vascular events in patients with stable vascular disease

181 aortic arch (AA) atheroma is associated with vascular events in patients with stroke or transient isc

182 than aspirin alone in preventing subsequent vascular events in patients with unstable angina, the co

183 There was no benefit for major vascular events in patients without multiple clinical ri

184 calculate adjusted relative risks for first vascular events in relation to physical activity.

185 he possible therapeutic utility of targeting vascular events in sepsis with cysteinyl-LT blockade.

186 Of 3096 acute cerebral or peripheral vascular events in the 92 728 study population, 383 inci

187 ere were 164 fewer first and 390 fewer total vascular events in the atorvastatin group (total events

188 roke have been described, who frequently had vascular events in the context of a pro-inflammatory hyp

189 daily) versus control for the prevention of vascular events in the UK.

190 e of hematologic malignancy, infections, and vascular events in younger patients.

191 and aspirin combination reduced the serious vascular event incidence by 25% (4.48% vs. 5.95%, hazard

192 h bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and

193 ndex stroke/TIA (range 0.5 to 4.5 years) for vascular events including stroke, TIA, myocardial infarc

194 ferative neoplasm that may be complicated by vascular events, including both thrombosis and bleeding.

195 line N-BNP was strongly predictive of future vascular events independently of other characteristics.

196 people living with HIV (PLWHIV), the risk of vascular events is increased; however, whether incidenta

197 fest vascular disease, the risk of recurrent vascular events is likely to vary.

198 nslate into a short-lived increased risk for vascular events is not known.

199 mation, but which of these are predictive of vascular events is not known.

200 k factor, how it causes end-organ damage and vascular events is poorly understood.

201 of AF-related stroke and peripheral embolic vascular events is uncertain.

202 on, or coronary revascularization) and major vascular events (major coronary events and ischemic stro

203 rticipants, with the risks of incident major vascular events, major coronary events, revascularizatio

204 n of FMD patients may present with a serious vascular event, many present with nonspecific symptoms a

205 resent on the OMV surface in mediating these vascular events, most likely via a mechanism that involv

206 udies (8,021 incident, 7,513 prevalent major vascular events [MVE] in 74,683 individuals) and 10 acut

207 pg/ml had adjusted relative risks for major vascular events (MVEs) (i.e., major coronary events [MCE

208 median 10.0 years of follow-up, 52,251 major vascular events (MVEs), including 7,326 major coronary e

209 New vascular events (myocardial infarction, stroke, or vascu

210 We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascu

211 [CI] 1.86 to 5.65; p = 0.0001) for nonfatal vascular events (n = 149), 1.80 (95% CI 1.13 to 2.88; p

212 were infections after discharge (n = 10) and vascular events (n = 6).

213 ring significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1

214 The primary outcome was the first major vascular event (nonfatal myocardial infarction, death fr

215 Major vascular events occurred in 1477 (24.5%) participants al

216 Antiplatelet Trialists' Collaboration vascular events occurred in 15 (7%), 13 (5%), and 8 (3%)

217 2024 acute vascular events occurred in 1657 individuals: 918 (45%)

218 irect evidence for the importance of ECAS in vascular events occurrence.

219 sed all individuals presenting with an acute vascular event of any type in any arterial territory irr

220 uclear estrogen receptor signaling regulates vascular events of physiological relevance and suggest t

221 jor adverse cardiovascular events, and major vascular events of the arm at 60 days.

222 The reduced risk of major vascular events on aspirin was initially offset by an in

223 ermine the effect of secondary prevention of vascular events on cognitive function after stroke.

224 et the patients at highest risk of recurrent vascular events on medical therapy.

225 let treatment is recommended after ischaemic vascular events, on the basis of trials done mainly in p

226 The primary outcome was the first major vascular event or revascularization.

227 hout aura did not have increased risk of any vascular events or angina.

228 ion, treated brain metastases, and no recent vascular events or bleeding diatheses were eligible.

229 or was not better than aspirin in preventing vascular events or death after stroke or TIA.

230 e with diabetes risk factors, a total of 134 vascular events or deaths were avoided for every 54 new

231 For such individuals, a total of 86 vascular events or deaths were avoided with no new cases

232 o 2 and no history of clinically significant vascular events or evidence of intestinal obstruction.

233 nsignificant reductions in the rate of major vascular events or revascularization for patients treate

234 The rates of total major vascular events or revascularization were significantly

235 e rates of medication adherence, total major vascular events or revascularization, the first major va

236 ated with an increase in fatal and non-fatal vascular events (OR 2.58, 95% CI 2.05-3.24, p<0.0001).

237 poB, and a corresponding lower risk of major vascular events (OR, 0.946 [95% CI, 0.921-0.972]) that w

238 ductions in the separate components of major vascular events, or meaningful differences in lipid resp

239 s, and the composite of stroke, death, major vascular events, or myocardial infarction using multivar

240 al cardiac events, and nonfatal extracardiac vascular events over a mean period of 7.8 years +/- 1.5

241 Treatment effects on total adjudicated vascular events, overall and by vascular territory, were

242 evels had a 3.8-fold increase in risk of any vascular event (P<0.001).

243 core was associated with risk for both major vascular events (P(trend)=0.005) and major coronary even

244 nteraction)=0.02; 2.7% versus 1.7% for major vascular events, P(interaction)<0.0001).

245 The Periodontitis and Vascular Events (PAVE) pilot study was conducted to inve

246 In the Periodontitis and Vascular Events (PAVE) pilot study, periodontal therapy

247 The RR for major vascular events per 1-mmol/L (38.7-mg/dL) reduction in L

248 0.77 (95% CI, 0.75-0.79, P < .001) for major vascular events per 1-mmol/L reduction in LDL-C level.

249 ed, similar proportional reductions in major vascular events per 1.0 mmol/L LDL cholesterol reduction

250 R 0.75, 95% CI 0.70-0.80) reduction in major vascular events per 1.0 mmol/l reduction in low-density

251 p had an estimated 41.2 first and 62.7 total vascular events per 100 participants over 6 years.

252 Over 6 years, an estimated 20 vascular events per 100 participants were avoided with a

253 -C were associated with similar RRs of major vascular events per change in LDL-C.

254 ansient ischemic attack, the total number of vascular events prevented with atorvastatin was more tha

255 are at increased risk but have not yet had a vascular event (primary prevention).

256 The majority of the patients (60%) developed vascular events ranging from repeated thrombophlebitis,

257 associated with lower combined bleeding and vascular event rate (27% vs. 46%; p = 0.05), shorter med

258 ER participants with moderate CKD had higher vascular event rates (hazard ratio [HR]: 1.54, 95% confi

259 Vascular event rates were estimated for each treatment g

260 whether reducing inflammation will decrease vascular event rates.

261 re 28-day mortality, recurrent stroke, major vascular events (recurrent stroke, myocardial infarction

262 pirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, s

263 ct of pneumococcal polysaccharide vaccine on vascular events remains controversial.

264 r transfer protein (CETP) inhibition reduces vascular event risk, but confusion surrounds its effects

265 is highly beneficial regarding mortality and vascular event risks.

266 cid and the relative risk reduction in major vascular events (RR 0.96 [95% CI, 0.89-1.03]).

267 d with a 7% relative risk reduction in major vascular events (RR, 0.93 [95% CI, 0.91-0.95]; P<0.0001)

268 l reductions in the aggregate of all serious vascular events seemed similar for men and women.

269 fety profile without obvious accumulation of vascular events, several types of vascular adverse event

270 andomised trials of aspirin in prevention of vascular events showed that daily aspirin reduced the in

271 lity and increased CIMT have associated with vascular events significantly (P < 0.05).

272 The rate of vascular events significantly increased in the first 4 w

273 ound no reduction in incidence of AF-related vascular events since publication of the BAFTA trial.

274 ough presence of metabolic syndrome predicts vascular events, such prediction is inferior and does no

275 rage risk, 43,000 person-years, 3306 serious vascular events) that compared long-term aspirin versus

276 grel Trial With Irbesartan for Prevention of Vascular Events, there was no evidence of interaction be

277 es the incidence of coronary and other major vascular events to a similar extent, irrespective of KIF

278 Clinical events comprised death, vascular events, tricuspid regurgitation requiring surge

279 ed an independent effect of LOOH on nonfatal vascular events, vascular procedures, and all events or

280 se, median 10-year risk of a recurrent major vascular event was 17% (interquartile range, 11%-28%), v

281 Cumulative 20-year risk of any vascular event was 27.7% (95% CI = 18.5-37.0) after TIA

282 or nonfatal myocardial infarction, and major vascular event was pre-defined as major coronary event p

283 , the risk (hazard ratio [HR]) of developing vascular events was assessed in patients with and withou

284 An increased risk for arterial and venous vascular events was seen in patients with CML treated wi

285 5.8% versus 11.4% (P < .001), and thrombotic vascular events were 2.8% versus 1.4% (P = .038), respec

286 ease-activated receptor-1 antagonism on limb vascular events were accompanied by an increased risk of

287 A past or presenting history of vascular events were common: 19.2% of patients had a tra

288 5 trials of statin therapy with 20 962 major vascular events were included, for a total of 374 358 pa

289 22.3 mg/dL]) from 49 trials with 39645 major vascular events were included.

290 idence rate of acute thrombosis, and develop vascular events when additional thrombosis risk factors

291 rivaroxaban and aspirin prevented 33 serious vascular events, whereas in lower-risk patients, rivarox

292 sets of patients at higher risk of recurrent vascular events, which may help focus the use of rivarox

293 The 6% (SE 3.5%) reduction in major vascular events with a further 0.35 mmol/L reduction in

294 Proportional reductions in the risk of major vascular events with anacetrapib did not differ signific

295 rapy significantly reduced the risk of major vascular events with greater potential for absolute bene

296 dered for primary or secondary prevention of vascular events with regard to the 2 independent risk fa

297 Proportional reductions in the risk of major vascular events with statin therapy were similar (intera

298 nt, especially in terms of the likelihood of vascular events, with 5' mutations most detrimental.

299 a significant reduction in the rate of major vascular events, with improved net clinical benefit.

300 of $100,000/QALY, the annual risk of serious vascular events would have to be >/=2.5 times higher wit